Perceptic | $12,000,000 | (Jun 2, 2026)
Invertix | $1,977,831 | (Jun 2, 2026)
XCENA | $135,000,000 | (Jun 2, 2026)
Korsana Biosciences
United States
- Waltham, MA
- 19/02/2026
- Unknown
- $175,000,000
Korsana Biosciences is a private biopharmaceutical company advancing a pipeline of potential best-in-class therapies for neurodegenerative diseases. In partnership with Paragon Therapeutics, we have developed Therapeutic Targeting (THETA™), a novel blood-brain barrier-penetrant shuttle platform designed to enable dramatically higher drug concentration inside the brain and overcome the limitations of earlier shuttle technologies. Our lead program is KRSA-028, an investigational, shuttled antibody targeting amyloid beta designed to be a best-in-class treatment for Alzheimer’s disease. Our mission is to advance precision-engineered therapies, designed to address some of the biggest unmet needs in medicine. For more information, please visit www.korsana.com
- Industry Biotechnology Research
- Website https://korsana.com/
- LinkedIn https://www.linkedin.com/company/korsana-biosciences/
Related People
Jonathan ViolinFounder
United States -
Seasoned CEO, board member, and accomplished scientist passionate about leading drug discovery and development, building effective scientific platforms, and forging relationships that drive company creation, growth, and financing. Raised over $1B in capital for public and private biotech companies. Recognized for strategic leadership, integrity, clear communication of scientific and clinical concepts, and fostering transparency and credibility with internal and external stakeholders.
Inherent | $50,000,000 | (Jun 2, 2026)
Gray Swan | $40,000,000 | (Jun 2, 2026)
Handshake(UK) | $3,200,000 | (Jun 2, 2026)
Sekai(US) | $26,000,000 | (Jun 2, 2026)
Human Archive (YC W26) | $8,200,000 | (Jun 2, 2026)
SpeedLabs | $6,500,000 | (Jun 2, 2026)
Reactor | $59,000,000 | (May 29, 2026)
MokN | $15,000,000 | (May 29, 2026)
Orebella | Undisclosed Amount | (May 29, 2026)